1. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111–8.
2. UDENYCA (pegfilgrastim-cbqv) injection, for subcutaneous use. Package insert. Coherus BioSciences Inc.; 2022.
3. Neulasta (pegfilgrastim) injection single-dose prefilled syringe. Package Insert. Amgen, Inc.; 2021.
4. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic growth factors Version 2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed April 23, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN, National Comprehensive Cancer Network® (NCCN®)